Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: Justification for K-ras-directed therapy

Molecular Cancer Research

Volumn 3, Issue 7, 2005, Pages 413-423

  Fleming, Jason B ^a   Shen, Guo Liang ^a   Holloway, Shane E ^a   Davis, Mishel ^a   Brekken, Rolf A ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE TRANSPORTER 1; INTEGRIN; RNA; THROMBOSPONDIN 1; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; ONCOGENE C MYC; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS CELL; PRIORITY JOURNAL; RNA INTERFERENCE;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENE THERAPY; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; PANCREATIC NEOPLASMS; RNA INTERFERENCE; RNA, CATALYTIC; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 22944447177     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-04-0206     Document Type: Article

References (62)

1. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004; 101:3-27.
2. Schmidt CM, Powell ES, Yiannoutsos CT, et al. Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg 2004;139:718-27.
3. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731-4.
4. Lemoine NR, Jain S, Hughes CM, et al. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992;102:230-6.
5. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22.
6. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363: 1049-57.
7. Leach SD. Mouse models of pancreatic cancer: the fur is finally flying! Cancer Cell 2004;5:7-11.
8. Sebti SM, Adjei AA. Farnesyltransferase inhibitors. Semin Oncol 2004;31: 28-39.
9. Saad ED, Hoff PM. Molecular-targeted agents in pancreatic cancer. Cancer Control 2004;11:32-8.
10. Kita K, Saito S, Morioka CY, Watanabe A. Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. Int J Cancer 1999;80:553-8.
11. Wickstrom E. Oligonucleotide treatment of ras-induced tumors in nude mice. Mol Biotechnol 2001;18:35-55.
12. Aoki K, Ohnami S, Yoshida T. Suppression of pancreatic and colon cancer cells by antisense K-ras RNA expression vectors. Methods Mol Med 2004;106: 193-204.
13. Yoshida T, Ohnami S, Aoki K. Development of gene therapy to target pancreatic cancer. Cancer Sci 2004;95:283-9.
14. MacKenzie MJ. Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol 2004;5:541-9.
15. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002;2:243-7.
16. Gitlin L, Karelsky S, Andino R. Short interfering RNA confers intracellular antiviral immunity in human cells. Nature 2002;418:430-4.
17. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003;5:834-9.
18. Telford WG, King LE, Fraker PJ. Comparative evaluation of several DNA binding dyes in the detection of apoptosis-associated chromatin degradation by flow cytometry. Cytometry 1992;13:137-43.
19. Moore A, Donahue CJ, Bauer KD, Mather JP. Simultaneous measurement of cell cycle and apoptotic cell death. Methods Cell Biol 1998;57:265-78.
20. Ito H, Duxbury M, Zinner MJ, Ashley SW, Whang EE. Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. Surgery 2004;136:548-56.
21. Duxbury MS, Ito H, Benoit E, Ashley SW, Whang EE. CEACAM6 is a determinant of pancreatic adenocarcinoma cellular invasiveness. Br J Cancer 2004;91:1384-90.
22. Albo D, Berger DH, Tuszynski GP. The effect of thrombospondin-1 and TGF-β1 on pancreatic cancer cell invasion. J Surg Res 1998;76:86-90.
23. Reinmuth N, Parikh AA, Ahmad SA, et al. Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc Res Tech 2003;60:199-207.
24. Takeda A, Stoeltzing O, Ahmad SA, et al. Role of angiogenesis in the development and growth of liver metastasis. Ann Surg Oncol 2002;9:610-6.
25. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
26. Watnick RS, Cheng Y-N, Rangarajan A, Ince TA, Weinberg RA. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003;3:219-31.
27. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
28. Warburg O. On respiratory impairment in cancer cells. Science 1956;124: 269-70.
29. Osthus RC, Shim H, Kim S, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 2000;275:21797-800.
30. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
31. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983;304: 596-602.
32. Leder A, Pattengale PK, Kuo A, Stewart TA, Leder P. Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development. Cell 1986;45:485-95.
33. Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 1987;49:465-75.
34. D'Cruz CM, Gunther EJ, Boxer RB, et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 2001;7:235-9.
35. Yeh E, Cunningham M, Arnold H, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 2004;6:308-18.
36. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999;4:199-207.
37. Felsher DW, Bishop JM. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci USA 1999;96: 3940-4.
38. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 1999;3:565-77.
39. Jain M, Arvanitis C, Chu K, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002;297:102-4.
40. Donaldson TD, Duronio RJ. Cancer cell biology: Myc wins the competition. Curr Biol 2004;14:R425-7.
41. O'Connell BC, Cheung AF, Simkevich CP, et al. A large scale genetic analysis of c-Myc-regulated gene expression patterns. J Biol Chem 2003;278: 12563-73.
42. Feinberg MW, Watanabe M, Lebedeva MA, et al. Transforming growth factor-β1 inhibition of vascular smooth muscle cell activation is mediated via Smad3. J Biol Chem 2004;279:16388-93.
43. Frederick JP, Liberati NT, Waddell DS, Shi Y, Wang XF. Transforming growth factor β-mediated transcriptional repression of c-myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element. Mol Cell Biol 2004;24:2546-59.
44. Rak J, Yu JL. Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand." Semin Cancer Biol 2004;14:93-104.
45. Knies-Bamforth UE, Fox SB, Poulsom R, Evan GI, Harris AL. c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Res 2004;64:6563-70.
46. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000;14:2501-14.
47. Hipfner DR, Cohen SM. Connecting proliferation and apoptosis in development and disease. Nat Rev Mol Cell Biol 2004;5:805-15.
48. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 1997;385:544-8.
49. Yan Z, Chen M, Perucho M, Friedman E. Oncogenic Ki-ras but not oncogenic Ha-ras blocks integrin β1-chain maturation in colon epithelial cells. J Biol Chem 1997;272:30928-36.
50. Yan Z, Deng X, Chen M, et al. Oncogenic c-Ki-ras but not oncogenic c-Ha-ras up-regulates CEA expression and disrupts basolateral polarity in colon epithelial cells. J Biol Chem 1997;272:27902-7.
51. Brakebusch C, Wennerberg K, Krell HW, et al. β1 integrin promotes but is not essential for metastasis of ras-myc transformed fibroblasts. Oncogene 1999; 18:3852-61.
52. Korah R, Boots M, Wieder R. Integrin α5β1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow. Cancer Res 2004;64:4514-22.
53. Corbi AL, Jensen UB, Watt FM. The α2 and α5 integrin genes: identification of transcription factors that regulate promoter activity in epidermal keratinocytes. FEBS Lett 2000;474:201-7.
54. Zhu S, Oh HS, Shim M, Sterneck E, Johnson PF, Smart RC. C/EBPβ modulates the early events of keratinocyte differentiation involving growth arrest and keratin 1 and keratin 10 expression. Mol Cell Biol 1999;19:7181-90.
55. Zhu S, Yoon K, Sterneck E, Johnson PF, Smart RC. CCAAT/enhancer binding protein-β is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic Ras signaling. Proc Natl Acad Sci U S A 2002;99:207-12.
56. Shiio Y, Donohoe S, Yi EC, Goodlett DR, Aebersold R, Eisenman RN. Quantitative proteomic analysis of Myc oncoprotein function. EMBO J 2002;21: 5088-96.
57. van Golen CM, Soules ME, Grauman AR, Feldman EL. N-Myc overexpression leads to decreased β1 integrin expression and increased apoptosis in human neuroblastoma cells. Oncogene 2003;22:2664-73.
58. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987;235:1492-5.
59. Yamamoto T, Seino Y, Fukumoto H, et al. Over-expression of facultative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990; 170:223-30.
60. Ogawa J, Inoue H, Koide S. Glucose-transporter-type-I-gene amplification correlates with sialyl-Lewis-X synthesis and proliferation in lung cancer. Int J Cancer 1997;74:189-92.
61. Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer 2001;92:634-41.
62. Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heel of cancer. Science 2002;297:63-4.